26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A cluster of phosphorylation sites in LRRK2 (leucine-rich repeat kinase 2), including Ser 910, Ser 935, Ser 955 and Ser 973, is important for PD (Parkinson’s disease) pathogenesis as several PD-linked LRRK2 mutants are dephosphorylated at these sites. LRRK2 is also dephosphorylated in cells after pharmacological inhibition of its kinase activity, which is currently proposed as a strategy for disease-modifying PD therapy. Despite this importance of LRRK2 dephosphorylation in mutant LRRK2 pathological mechanism(s) and in LRRK2’s response to inhibition, the mechanism by which this occurs is unknown. Therefore we aimed to identify the phosphatase for LRRK2. Using a panel of recombinant phosphatases, we found that PP1 (protein phosphatase 1) efficiently dephosphorylates LRRK2 in vitro. PP1 activity on LRRK2 dephosphorylation was confirmed in cells using PP1 inhibition to reverse LRRK2 dephosphorylation induced by the potent LRRK2 kinase inhibitor LRRK2-IN1 as well as in R1441G mutant LRRK2. We also found that PP1 and LRRK2 can form a complex in cells. Furthermore, we observed that PP1 inhibition modulates LRRK2’s cellular phenotype by reducing skein-like LRRK2-positive structures associated with dephosphorylation. In conclusion, the present study reveals PP1 as the physiological LRRK2 phosphatase, responsible for LRRK2 dephosphorylation observed in PD mutant LRRK2 and after LRRK2 kinase inhibition.

          Related collections

          Author and article information

          Journal
          2984726R
          1011
          Biochem J
          Biochem. J.
          The Biochemical journal
          0264-6021
          1470-8728
          30 November 2016
          15 November 2013
          07 December 2016
          : 456
          : 1
          : 119-128
          Affiliations
          [* ]Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences, KU Leuven, Kapucijnenvoer 33,3000 Leuven, Belgium
          []The Parkinson’s Institute, 675 Almanor Ave. Sunnyvale, CA 94085, U.S.A
          []Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20892, U.S.A
          [§ ]Primary and Stem Cell Systems, Life Technologies Corporation, 501 Charmany Drive, Madison, WI 53719, U.S.A
          []Laboratory for Biosignaling and Therapeutics, Department of Cellular and Molecular Medicine, KU Leuven, O&N I Herestraat 49-box 901, 3000 Leuven, Belgium
          Author notes
          [2 ]Correspondence may be addressed to either of these authors ( jnichols@ 123456parkinsonsinstitute.org or jean-marc.taymans@ 123456med.kuleuven.be )
          [1]

          These authors contributed equally to this study.

          [3]

          R. Jeremy Nichols is a consultant for Life Technologies Corporation.

          Article
          PMC5141581 PMC5141581 5141581 nihpa739070
          10.1042/BJ20121772
          5141581
          23937259
          fba57b86-b609-4117-8c70-5790733ba6db
          History
          Categories
          Article

          leucine-rich repeat kinase 2 (LRRK2),protein phosphatase 1 (PP1),Parkinson’s disease,phosphorylation,phosphatase inhibition,skein-like structure

          Comments

          Comment on this article